A study to investigate the effect of taking fenofibrate on abnormal artery blood vessel function in people with Type 2 diabetes who are on best-dose treatment with statin medications.

INTERVENTION: 12 week crossover study comparing Fenofibrate 145mg orally daily or placebo in subjects with Type 2 Diabetes who are receiving optimal dose statin therapy CONDITION: Endothelial dysfunction in Type 2 Diabetes PRIMARY OUTCOME: Brachial artery ultrasound: change in %FMD (flow mediated dilatation, endothelium‐mediated). SECONDARY OUTCOME: 1. Forearm plethysmography: changes in forearm blood flow. 2. Non‐invasive measures of arterial stiffness (applanation tonometry and arterial pulse wave analysis: Small and larger artery compliance, Augmetnation index, and Pulse Wave Velocity). 3. Biological markers. INCLUSION CRITERIA: Type 2 diabetes aged 40‐79 years; treatment with HMG‐CoA reductase inhibitor (statin) at a stable dose for >=6 weeks; fasting LDL‐cholesterol<2.5mmol/L; HDL‐cholesterol <=1.5mmol/L; brachial artery FMD <=5.50% on screening ultrasound.